2022 - Pharma Rep Focus

Editor's corner: Fierce Pharma's top 10 stories of 2022

Fierce Pharma

DECEMBER 21, 2022

Editor's corner: Fierce Pharma's top 10 stories of 2022. Wed, 12/21/2022 - 08:42. esagonowsky.

Pharma

After 2022's M&A spree, Amgen CEO Bradway collects $21.4M payday

Fierce Pharma

APRIL 7, 2023

After 2022's M&A spree, Amgen CEO Bradway collects $21.4M payday zbecker Fri, 04/07/2023 - 12:10

AbbVie CEO Gonzalez scored $26M in 2022 pay as cash cow Humira neared patent cliff

Fierce Pharma

MARCH 7, 2023

AbbVie CEO Gonzalez scored $26M in 2022 pay as cash cow Humira neared patent cliff aliu Tue, 03/07/2023 - 10:54

A realistic view of healthcare in 2022

World of DTC Marketing

JANUARY 1, 2022

The post A realistic view of healthcare in 2022. It’saper to bet on a small molecule in development than add more money to R&D. 10en: Omnichannel marketing has become more critical in marketing to HCPs – The salesforce still has value for some specialties, but omnichannel marketing will be the key to reaching HCPs.

Healthcare

Healthcare Healthcare Side effects Prescription

Going to Market Smarter in the New Economy

Advertiser: ZoomInfo

In 2022, as companies continue to move more functions online, employees will take a more virtual -- and flexible -- mindset and lifestyle in parallel to the digitization of businesses. The fight to find new customers and retain existing ones is the biggest business challenge for many companies.

Marketing

Eli Lilly CEO racked up $21.4M in 2022 pay as stock price hit all-time high

Fierce Pharma

MARCH 20, 2023

in 2022 pay as stock price hit all-time high aliu Mon, 03/20/2023 - 10:51 Eli Lilly CEO racked up $21.4M

Coming and going paid off for biopharma CEOs in 2022

Fierce Pharma

JUNE 26, 2023

There was a decline in CEO compensation overall in 2022. But there was no evidence of the slide in biopharma where pay increases were plentiful.

Biopharma

High-flying Vertex hikes CEO Reshma Kewalramani's pay by 30% to $20.6M

Fierce Pharma

APRIL 5, 2024

million pay in 2022. Vertex CEO Reshma Kewalramani, M.D., million in 2023, which was an increase of 30% from her $15.9

AstraZeneca withdraws US COVID vaccine application, shifts focus to antibody treatments

Fierce Pharma

NOVEMBER 10, 2022

Thu, 11/10/2022 - 09:02. AstraZeneca withdraws US COVID vaccine application, shifts focus to antibody treatments.

The ABC’s of Recruiting for Gen Z

Advertiser: ZoomInfo

In 2022, society has fully immersed itself in the web and all it has to offer - and no one more so than those of Generation Z. Take a look around you at any given moment, and somebody is likely surfing the web on their phone.

Recruitment

Arcutis' Zoryve bags 2nd FDA nod, this time as a foam to treat 'the great neglected disease in dermatology'

Fierce Pharma

DECEMBER 15, 2023

About a year after Arcutis Biotherapeutics unveiled positive data on roflumilast foam at the European Academy of Dermatology and Venereology congress 2022, the company has clinched a second FDA OK.

FDA

With Pfizer struggling in 2023, CEO Bourla hit with 35% pay cut to $21.6M

Fierce Pharma

MARCH 15, 2024

After a difficult year for Pfizer, in which its share price fell by 44%, CEO Albert Bourla’s compensation fell by 35% from $33 million in 2022 to $21.6 But even the drugmaker was surprised by the plummeting demand for its COVID-19 products, missing badly on its 2023 guidance. million in 2023.

Pfizer, Sanofi settle first California Zantac case slated for trial: report

Fierce Pharma

DECEMBER 22, 2022

Thu, 12/22/2022 - 12:38. Pfizer, Sanofi settle first California Zantac case slated for trial: report.

AbbVie pumps $223M into Singapore biologics plant, plots 100 hires

Fierce Pharma

JANUARY 26, 2024

In late 2022, GSK, Sanofi and Takeda signed on with a partnership of local agencies to advance biologic manufacturing in Singapore. | In late 2022, GSK, Sanofi and Takeda signed on with a partnership of local agencies to advance biologic manufacturing in Singapore.

Manufacturing

What We Learned From Our Own Data-Driven ABM Strategy

Advertiser: ZoomInfo

So, what does ABM look like in 2022? Analysts and professionals alike tend to argue that account based marketing (ABM) is not new. On the surface, this is an accurate statement. However, ABM practitioners have evolved the strategy from development to implementation.

Marketing

Bavarian Nordic scores $157M contract to replenish US supplies of smallpox/mpox vaccine Jynneos

Fierce Pharma

AUGUST 8, 2024

million to “partly replenish” Jynneos vaccine stocks in response to the 2022 outbreak of mpox, the disease formerly known as monkeypox. . | The Biomedical Advanced Research and Development Authority (BARDA) is handing Bavarian Nordic $156.8

Government

Roche scores FDA nod for prefilled syringe version of Vabysmo, easing its administration

Fierce Pharma

JULY 8, 2024

Since Roche gained approval for its eye disease medication Vabysmo in 2022, it has stormed a market dominated by Regeneron and Bayer’s Eylea. Since Roche gained approval for its eye disease medication Vabysmo in 2022, it has stormed a market dominated by Regeneron and Bayer’s Eylea.

FDA

FDA Doctors Medicine Medical

Report: MA Insurers Denied 3.4M Prior Authorization Requests in 2022

MedCity News

AUGUST 19, 2024

of prior authorization requests submitted to MA insurers were denied in 2022, according to a recent KFF report. Prior Authorization Requests in 2022 appeared first on MedCity News. About 7.4% Of these denials, only 9.9% were appealed. The post Report: MA Insurers Denied 3.4M

Insurance

Cancer center leaders lay bare CAR-T makers' struggles—and an unexpected laggard

Fierce Pharma

DECEMBER 13, 2022

Tue, 12/13/2022 - 20:12. Cancer center leaders lay bare CAR-T makers' struggles—and an unexpected laggard.

Marketing-Led COVID-19 Growth Strategies: 2022 and Beyond

Advertiser: ZoomInfo

More than two years into the pandemic, COVID-19 is far from over. Businesses are tasked with beating pre-pandemic numbers, making marketing more essential than ever before.

Marketing

Biogen, FDA's inappropriate Aduhelm coordination detailed in blistering congressional report

Fierce Pharma

DECEMBER 29, 2022

Thu, 12/29/2022 - 14:42. Biogen, FDA's inappropriate Aduhelm coordination detailed in blistering congressional report. aarmstrong.

FDA

ASH: Bristol Myers bolsters Breyanzi's case in earlier lymphoma amid clash with Gilead

Fierce Pharma

DECEMBER 9, 2022

Fri, 12/09/2022 - 09:15. ASH: Bristol Myers bolsters Breyanzi's case in earlier lymphoma amid clash with Gilead.

Moderna’s Spikevax carries higher risk of myocarditis than Pfizer's Comirnaty, study says

Fierce Pharma

NOVEMBER 8, 2022

Tue, 11/08/2022 - 11:03. Moderna’s Spikevax carries higher risk of myocarditis than Pfizer's Comirnaty, study says.

Atara makes history with world-first nod for allogeneic T-cell therapy Ebvallo

Fierce Pharma

DECEMBER 19, 2022

Mon, 12/19/2022 - 14:06. Atara makes history with world-first nod for allogeneic T-cell therapy Ebvallo. fkansteiner.

With $1.2B stock sale, GSK offloads more of its stake in consumer health spinoff Haleon

Fierce Pharma

JANUARY 17, 2024

GSK is sticking to its plan to gradually monetize its stake in Haleon, the consumer health business the British pharma giant spun off in 2022. | GSK is sticking to its plan to gradually monetize its stake in Haleon, the consumer health business the British pharma giant spun off in 2022.

Sales

Sales Pharma

GSK's CAR-T rival Blenrep fails multiple myeloma trial, endangering its accelerated approval

Fierce Pharma

NOVEMBER 7, 2022

Mon, 11/07/2022 - 09:45. GSK's CAR-T rival Blenrep fails multiple myeloma trial, endangering its accelerated approval.

ASH: CSL, uniQure's gene therapy Hemgenix shows durable protection in hemophilia B

Fierce Pharma

DECEMBER 12, 2022

Mon, 12/12/2022 - 14:25. ASH: CSL, uniQure's gene therapy Hemgenix shows durable protection in hemophilia B.

NICE gives thumbs-down to 5 COVID-19 drugs including AZ's Evusheld and Merck's Lagevrio

Fierce Pharma

NOVEMBER 16, 2022

Wed, 11/16/2022 - 09:44. NICE gives thumbs-down to 5 COVID-19 drugs including AZ's Evusheld and Merck's Lagevrio.

With buyout on Horizon, Amgen and Sanofi eye cash plays for rare disease drug maker

Fierce Pharma

DECEMBER 2, 2022

Fri, 12/02/2022 - 09:51. With buyout on Horizon, Amgen and Sanofi eye cash plays for rare disease drug maker. fkansteiner.

Sporting a $3.5M price tag, CSL and uniQure's hemophilia B gene therapy crosses FDA finish line

Fierce Pharma

NOVEMBER 23, 2022

Wed, 11/23/2022 - 10:10. Sporting a $3.5M price tag, CSL and uniQure's hemophilia B gene therapy crosses FDA finish line.

FDA

Nothing to sneeze at: AstraZeneca donates thousands of nasal spray flu vaccines after Swiss pricing row

Fierce Pharma

NOVEMBER 17, 2022

Thu, 11/17/2022 - 13:27. Nothing to sneeze at: AstraZeneca donates thousands of nasal spray flu vaccines after Swiss pricing row. fkansteiner.

As mpox outbreak spreads across Africa, Siga's antiviral Tpoxx misses the bar in Congo study

Fierce Pharma

AUGUST 15, 2024

Just as a new strain of mpox spreads across Africa, results from a preliminary analysis of a study that began during the 2022 viral outbreak stands to provide more clarity on the clinical benefit o | Despite missing the trial's primary endpoint of time to lesion resolution, the study suggested that the treatment may be most beneficial for those (..)

Senators blast Pfizer's proposed COVID vaccine price hike as 'profiteering'

Fierce Pharma

DECEMBER 14, 2022

Wed, 12/14/2022 - 09:00. Senators blast Pfizer's proposed COVID vaccine price hike as 'profiteering'. fkansteiner.

Senator presses Amgen with 'final request' for information in tax probe

Fierce Pharma

DECEMBER 9, 2022

Fri, 12/09/2022 - 09:50. Senator presses Amgen with 'final request' for information in tax probe.

On a roll, Takeda's dengue vaccine shifts into FDA's fast review lane

Fierce Pharma

NOVEMBER 23, 2022

Wed, 11/23/2022 - 09:35. On a roll, Takeda's dengue vaccine shifts into FDA's fast review lane.

FDA

Who's No. 1? With $25B in sales, Merck's Keytruda looks to be the top-selling drug of 2023

Fierce Pharma

FEBRUARY 1, 2024

billion in 2022 and $55.1 With Merck reporting a whopping $25 billion sales haul for | With Merck reporting a whopping $25 billion sales haul for Keytruda on Thursday, the PD-1 cancer superstar appears to be the world’s top-selling drug in 2023. billion in 2021.

Sales

Watch out, Amgen. Mirati kicks off KRAS showdown with FDA approval for Krazati

Fierce Pharma

DECEMBER 12, 2022

Mon, 12/12/2022 - 18:14. Watch out, Amgen. Mirati kicks off KRAS showdown with FDA approval for Krazati.

FDA

Genentech starts phase 2 trial to optimize delivery of eye disease cell therapy

Fierce Pharma

NOVEMBER 28, 2022

Mon, 11/28/2022 - 10:11. Genentech starts phase 2 trial to optimize delivery of eye disease cell therapy.

Novartis prunes nearly 300 jobs in Garden State as corporate slimdown rolls on

Fierce Pharma

DECEMBER 19, 2022

Mon, 12/19/2022 - 10:53. Novartis prunes nearly 300 jobs in Garden State as corporate slimdown rolls on. fkansteiner.

Senator aims to cut biosimilar 'red tape' with proposal to eliminate interchangeable status

Fierce Pharma

NOVEMBER 23, 2022

Wed, 11/23/2022 - 07:18. Senator aims to cut biosimilar 'red tape' with proposal to eliminate interchangeable status.

Activist shareholders ask 9 big pharmas to consider whether 'excessive' patenting hurts access

Fierce Pharma

DECEMBER 15, 2022

Thu, 12/15/2022 - 10:51. Activist shareholders ask 9 big pharmas to consider whether 'excessive' patenting hurts access.

Pharma

After overcoming vial issue, Gilead wins FDA approval for long-acting HIV injectable Sunlenca

Fierce Pharma

DECEMBER 21, 2022

Wed, 12/21/2022 - 17:50. After overcoming vial issue, Gilead wins FDA approval for long-acting HIV injectable Sunlenca.

FDA

AstraZeneca, Merck hit with 3-month delay for Lynparza's FDA filing in first-line prostate cancer

Fierce Pharma

DECEMBER 15, 2022

Thu, 12/15/2022 - 09:53. AstraZeneca, Merck hit with 3-month delay for Lynparza's FDA filing in first-line prostate cancer.

FDA

Amgen's marketing efforts help boost Tepezza sales

Fierce Pharma

AUGUST 7, 2024

It was Tepezza’s highest quarterly sales figure since Q4 of 2022. In the second quarter, Tepezza generated $479 million in sales for an increase of 8% year over year and 13% sequentially.

Sales

Sales Marketing

Editor's corner: Fierce Pharma's top 10 stories of 2022

After 2022's M&A spree, Amgen CEO Bradway collects $21.4M payday

Trending Sources

AbbVie CEO Gonzalez scored $26M in 2022 pay as cash cow Humira neared patent cliff

A realistic view of healthcare in 2022

Going to Market Smarter in the New Economy

Eli Lilly CEO racked up $21.4M in 2022 pay as stock price hit all-time high

Coming and going paid off for biopharma CEOs in 2022

High-flying Vertex hikes CEO Reshma Kewalramani's pay by 30% to $20.6M

AstraZeneca withdraws US COVID vaccine application, shifts focus to antibody treatments

The ABC’s of Recruiting for Gen Z

Arcutis' Zoryve bags 2nd FDA nod, this time as a foam to treat 'the great neglected disease in dermatology'

With Pfizer struggling in 2023, CEO Bourla hit with 35% pay cut to $21.6M

Pfizer, Sanofi settle first California Zantac case slated for trial: report

AbbVie pumps $223M into Singapore biologics plant, plots 100 hires

What We Learned From Our Own Data-Driven ABM Strategy

Bavarian Nordic scores $157M contract to replenish US supplies of smallpox/mpox vaccine Jynneos

Roche scores FDA nod for prefilled syringe version of Vabysmo, easing its administration

Report: MA Insurers Denied 3.4M Prior Authorization Requests in 2022

Cancer center leaders lay bare CAR-T makers' struggles—and an unexpected laggard

Marketing-Led COVID-19 Growth Strategies: 2022 and Beyond

Biogen, FDA's inappropriate Aduhelm coordination detailed in blistering congressional report

ASH: Bristol Myers bolsters Breyanzi's case in earlier lymphoma amid clash with Gilead

Moderna’s Spikevax carries higher risk of myocarditis than Pfizer's Comirnaty, study says

Atara makes history with world-first nod for allogeneic T-cell therapy Ebvallo

With $1.2B stock sale, GSK offloads more of its stake in consumer health spinoff Haleon

GSK's CAR-T rival Blenrep fails multiple myeloma trial, endangering its accelerated approval

ASH: CSL, uniQure's gene therapy Hemgenix shows durable protection in hemophilia B

NICE gives thumbs-down to 5 COVID-19 drugs including AZ's Evusheld and Merck's Lagevrio

With buyout on Horizon, Amgen and Sanofi eye cash plays for rare disease drug maker

Sporting a $3.5M price tag, CSL and uniQure's hemophilia B gene therapy crosses FDA finish line

Nothing to sneeze at: AstraZeneca donates thousands of nasal spray flu vaccines after Swiss pricing row

As mpox outbreak spreads across Africa, Siga's antiviral Tpoxx misses the bar in Congo study

Senators blast Pfizer's proposed COVID vaccine price hike as 'profiteering'

Senator presses Amgen with 'final request' for information in tax probe

On a roll, Takeda's dengue vaccine shifts into FDA's fast review lane

Who's No. 1? With $25B in sales, Merck's Keytruda looks to be the top-selling drug of 2023

Watch out, Amgen. Mirati kicks off KRAS showdown with FDA approval for Krazati

Genentech starts phase 2 trial to optimize delivery of eye disease cell therapy

Novartis prunes nearly 300 jobs in Garden State as corporate slimdown rolls on

Senator aims to cut biosimilar 'red tape' with proposal to eliminate interchangeable status

Activist shareholders ask 9 big pharmas to consider whether 'excessive' patenting hurts access

After overcoming vial issue, Gilead wins FDA approval for long-acting HIV injectable Sunlenca

AstraZeneca, Merck hit with 3-month delay for Lynparza's FDA filing in first-line prostate cancer

Amgen's marketing efforts help boost Tepezza sales

Stay Connected